- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07587255
Efficacy of Extracorporeal Shockwave Therapy on Plantar Fasciitis in Patients With Peripheral Neuropathy
12. mai 2026 oppdatert av: National Taiwan University Hospital
Efficacy of Extracorporeal Shockwave Therapy for Plantar Fasciitis in Patients With Peripheral Neuropathy: A Clinical Evaluation
This study aims to evaluate the efficacy of extracorporeal shockwave therapy (ESWT) in reducing pain and improving functional outcomes for patients with neuropathy-associated plantar fasciitis.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Plantar fasciitis is the most common cause of heel pain in clinical practice, accounting for approximately 80% of patients presenting with heel pain.
Common clinical presentations include unilateral or bilateral foot pain, particularly upon weight-bearing after a period of rest, such as the first steps in the morning.
Some patients may also report associated paresthesia, tingling, or a burning sensation.
Notably, a considerable number of patients with peripheral neuropathy (PN) also present with coexisting plantar fasciitis.
The proposed pathophysiological mechanisms underlying neuropathy-associated plantar fasciitis include progressive degeneration of the plantar fascia due to chronic somatosensory deficits, thickening of the plantar fascia secondary to metabolic syndromes such as diabetic neuropathy, and the loss of foot intrinsic muscle support due to motor nerve involvement.
Conventional treatments for plantar fasciitis include nonsteroidal anti-inflammatory drugs (NSAIDs), local corticosteroid injections, and custom orthotics; however, these interventions exhibit significant limitations.
While NSAIDs may provide temporary analgesia, their long-term utility is limited by systemic risks, particularly gastrointestinal complications.
Local corticosteroid injections effectively reduce inflammation and provide acute symptom relief; however, they carry a risk of plantar fascia rupture, rendering repeated administration clinically unfavorable.
Orthotic insoles redistribute biomechanical loading across the foot to reduce mechanical stress; however, they are primarily compensatory and do not facilitate tissue regeneration or fundamental repair of the chronic lesion.
Given these limitations in conventional treatments, this study aims to evaluate the efficacy of extracorporeal shockwave therapy (ESWT) in reducing pain and improving functional outcomes for patients with neuropathy-associated plantar fasciitis.
The investigators will assess the effects of ESWT on the pathophysiological mechanism of the neuropathic foot to alleviate the symptoms of plantar fasciitis in participants with peripheral neuropathy.
Findings of the investigation aim to validate the clinical application of non-invasive ESWT for this population, thereby enhancing their functional independence and health-related quality of life.
Studietype
Intervensjonell
Registrering (Antatt)
114
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: CHIEN-HO LIN, PT, PhD
- Telefonnummer: +886923662018
- E-post: chienhol@ntu.edu.tw
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Age 18 or older and 90 or younger.
- Ability to give informed consent.
- Presence of peripheral neuropathy, confirmed by clinical symptoms, nerve
- conduction study, autonomic function test, quantitative sensory test, or skin biopsy.
- Plantar fasciitis presenting as (1) heel pain persisting for more than 3 months, most noticeable with initial steps after a period of inactivity, but also worse following prolonged weight-bearing, and (2) pain with palpation of the proximal insertion of the plantar fascia.
Exclusion Criteria:
- Presence of severe systemic diseases, including severe ischemic heart disease or congestive heart failure (left ventricular ejection fraction < 30%), severe lung diseases with dyspnea, severe generalized edema, uncontrolled diabetes, and systemic infection.
- Presence of severe peripheral vascular disease.
- Presence of an implanted cardiac pacemaker, deep brain stimulator, or metallic implants (for example, internal fixation plates, screws, etc.) within the affected foot or ankle.
- Presence of ruptured or pre-ruptured tendons in the target area. A diagnostic softtissue ultrasound of the plantar foot will be performed to assess tissue integrity if any of the following clinical red flags are identified: localized soft-tissue swelling or ecchymosis; physical examination findings indicative of a loss of continuity or tension in the plantar fascia; a history of local corticosteroid injection within the past 12 months; or a history of surgical intervention involving the affected foot.
- Complete loss of vibration and pinprick sensation at the target area due to neuropathy, or the presence of severe mechanical allodynia (pain evoked by friction or pressure) at the target area with an intensity score of 8 or higher on the Numeric Rating Scale (NRS), where 0 represents no pain and 10 represents the most severe pain.
- Pregnancy.
- Coagulation disorders (including localized thrombosis in the target area).
- Patients currently receiving anticoagulant therapy.
- Presence of localized tumors or active bacterial and/or viral infections in the target area.
- Patients who have received corticosteroid injections within the past 6 weeks in the target area.
- Inability to give informed consent.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Extracorporeal shockwave therapy (ESWT)
Participants of the study will receive real or sham ESWT during the study period
|
Extracorporeal Shock Wave Therapy (ESWT) is a non-invasive treatment for plantar fasciitis, using acoustic waves to stimulate healing.
Participants enrolled in the study will receive real or sham ESWT.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Visual analogue scale of pain
Tidsramme: VAS scores will be recorded before and after each ESWT session, as well as two weeks post-intervention. Long-term follow-up evaluations will be conducted at 12 weeks and 12 months following the final treatment.
|
The Visual Analogue Scale (VAS) will be used to assess pain intensity, with scores ranging from 0 (no pain) to 10 (maximal unbearable pain).
|
VAS scores will be recorded before and after each ESWT session, as well as two weeks post-intervention. Long-term follow-up evaluations will be conducted at 12 weeks and 12 months following the final treatment.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. mai 2026
Primær fullføring (Antatt)
1. april 2031
Studiet fullført (Antatt)
1. mai 2032
Datoer for studieregistrering
Først innsendt
29. april 2026
Først innsendt som oppfylte QC-kriteriene
12. mai 2026
Først lagt ut (Faktiske)
14. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
14. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. mai 2026
Sist bekreftet
1. april 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Smerte
- Nevrologiske manifestasjoner
- Muskel- og skjelettsykdommer
- Sykdommer i nervesystemet
- Nevromuskulære sykdommer
- Fotsykdommer
- Patologiske tilstander, tegn og symptomer
- Tegn og symptomer
- Fasciitt
- Nevralgi
- Sykdommer i det perifere nervesystemet
- Fasciitt, Plantar
- Terapeutikk
- Fysioterapi -modaliteter
- Rehabilitering
- Ultrasonisk terapi
- Diatermi
- Hypertermi, indusert
- Ekstrakorporeal sjokkwaveterapi
Andre studie-ID-numre
- 202602044DINE
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .